Evidence map›Paper›PMID 39062774›Full record

ArticleInternational journal of molecular sciences2024

The Clinical Significance of

Laura Aleksandra Szafron, Roksana Iwanicka-Nowicka, Agnieszka Podgorska, Arkadiusz M Bonna, Piotr Sobiczewski, Jolanta Kupryjanczyk, Lukasz Michal Szafron

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Laura Aleksandra SzafronMaria Sklodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, Poland.ORCID 0000-0002-7542-3898
Roksana Iwanicka-NowickaLaboratory of Systems Biology, Faculty of Biology, University of Warsaw, 02-106 Warsaw, Poland.ORCID 0000-0003-1595-2170
Agnieszka PodgorskaCancer Molecular and Genetic Diagnostics Department, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, Poland.
Arkadiusz M BonnaTriple Helical Peptides Ltd., Cambridge CB22 5DU, UK.ORCID 0000-0002-3957-7849
Piotr SobiczewskiDepartment of Gynecological Oncology, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, Poland.
Jolanta KupryjanczykDepartment of Cancer Pathomorphology, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, Poland.
Lukasz Michal SzafronMaria Sklodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, Poland.ORCID 0000-0003-1670-0274

Funding

National Science Center 2016/23/D/NZ5/01453National Science Center 2020/37/B/NZ5/04215
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

DNA MethylationGene Expression Regulation, NeoplasticOvarian NeoplasmsPolymorphism, Single NucleotideRNA, Long NoncodingAdultAgedBiomarkers, TumorClinical RelevanceFemaleHumansMiddle AgedPrognosisPromoter Regions, GeneticBiomarkers, TumorCRNDE RNA, humanRNA, Long NoncodingCRNDECRNDEPDNA methylationDNA sequence variantIHClncRNAmicropeptideovarian cancerTP53

Identifiers

PMID39062774
PMCPMC11277161

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.